Orris

What is petreguem

Searching the Web

petreguem meaning

"Petreguem" doesn't appear to be a recognized word in English or any major language I'm aware of, and the web search didn't find a match either - only results for "petroleum" came up as the closest match.
A few possibilities:
  • Typo for "petroleum" - the dark, thick fossil fuel crude oil extracted from underground deposits
  • A regional/dialect word - it might be a term from a specific local language or dialect I don't have data on
  • A proper noun - a place name, brand, or personal name from a specific region
  • A misspelling - could you be thinking of a different word?
Could you share more context about where you came across "petreguem"? For example, is it from a specific language, a book, a game, or a location? That would help me give you a more accurate answer.

What is diabetic retinopathy

Reading File
Finding Sources
Searching PubMed

"diabetic retinopathy"[MeSH Terms] AND management

Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Loading Image
Here is a thorough, textbook-based overview of diabetic retinopathy (DR).

Diabetic Retinopathy

What Is It?

Diabetic retinopathy is a microvascular complication of diabetes mellitus that damages the blood vessels of the retina - the light-sensitive tissue lining the back of the eye. It is the most common cause of new blindness in working-age adults in industrialized countries. Around 40% of all people with diabetes have some degree of DR, and the prevalence in type 2 diabetes reaches 67% after 10 years. With effective screening and treatment, the risk of severe visual loss can be reduced to less than 5%.
  • Kanski's Clinical Ophthalmology, 10th ed., p. 521

Normal Retinal Anatomy (Baseline)

The retina relies on a network of fine capillaries supplied by endothelial cells and pericytes (supporting cells that regulate blood flow and vessel integrity).
Normal retinal capillary bed. (A) Periarteriolar capillary-free zone - flat Indian ink-injected preparation; (B) Endothelial cells with elongated nuclei and pericytes with rounded nuclei - trypsin digest preparation.
Normal retinal capillary bed - Kanski's Clinical Ophthalmology, p. 521

Pathogenesis (How It Develops)

The primary target tissue is the retinal capillary. Chronic hyperglycemia causes:
  1. Loss of pericytes - these are directly involved in DR pathogenesis; their loss destabilizes vessel walls
  2. Basement membrane thickening - weakens capillary structure
  3. Endothelial dysfunction - increases vascular permeability and promotes leakage
  4. Localized ischemia - triggers release of VEGF (vascular endothelial growth factor), which drives abnormal new vessel growth (neovascularization)
The result is a cascade of vascular events: microaneurysms, hemorrhages, exudates, macular edema, and eventually proliferative disease.
  • Robbins & Kumar Basic Pathology; Textbook of Family Medicine 9e

Classification (Disease Severity Scale)

StageKey Features
No apparent retinopathyNormal fundus
Mild NPDRMicroaneurysms only
Moderate NPDRMore than mild; may have cotton-wool spots (CWSs) and venous beading
Severe NPDR>20 intraretinal hemorrhages in all 4 quadrants, 2+ quadrants of venous beading, OR 1 quadrant of prominent intraretinal microvascular abnormalities (IRMA) - no PDR
PDR (Proliferative DR)Neovascularization of iris, disc, or retina; vitreous/preretinal hemorrhage
Diabetic Macular Edema (DME)Can occur at any stage; fovea-threatening DME requires treatment
  • The Wills Eye Manual, p. 811-812

Ophthalmic Complications of Diabetes

Common:
  • Diabetic macular edema (DME) and macular ischemia
  • Retinal ischemia leading to neovascularization and vitreous hemorrhage
  • Unstable refraction
Uncommon/Rare:
  • Neovascular glaucoma (NVG)
  • Tractional retinal detachment
  • Accelerated cataract
  • Ocular motor nerve palsies
  • Papillopathy

Risk Factors

  • Duration of diabetes - the single most important predictor; DR is rare in the first 5 years
  • Poor glycemic control - higher HbA1c = greater risk (DCCT and UKPDS trials confirmed tight glucose control reduces risk)
  • Hypertension - must be controlled to <140/80 mmHg; especially important in type 2 with maculopathy
  • Nephropathy - severe renal disease worsens DR
  • Pregnancy - can accelerate DR, especially if control was poor before pregnancy (up to 1/3 of those with moderate DR progress to PDR during pregnancy)
  • Hyperlipidemia, anemia, cataract surgery - additional risk factors
  • Drugs - pioglitazone is linked to worsening of diabetic macular edema
  • Kanski's Clinical Ophthalmology, p. 521-522

Workup / Investigations

  1. Slit-lamp examination with gonioscopy (check for neovascularization of iris/angle)
  2. Dilated fundus examination (90D or 60D lens; indirect ophthalmoscopy for periphery)
  3. HbA1c, fasting blood sugar, lipid panel
  4. Blood pressure check
  5. OCT - evaluates presence and extent of diabetic macular edema (DME)
  6. IVFA (intravenous fluorescein angiography) - assesses perfusion, foveal ischemia, microaneurysms
  7. OCT Angiography (OCTA) - non-invasive, detects central macular ischemia

Treatment

Diabetic Macular Edema (DME)

  1. Anti-VEGF agents - first-line for center-involving DME. FDA-approved agents: ranibizumab, aflibercept; off-label: bevacizumab
  2. Intravitreal corticosteroids - for suboptimal anti-VEGF response; FDA-approved: dexamethasone implant, fluocinolone acetonide. Side effects: cataract, raised intraocular pressure
  3. Focal macular laser - for extrafoveal microaneurysms causing edema; also used when injections are contraindicated

Proliferative Diabetic Retinopathy (PDR)

  1. Panretinal photocoagulation (PRP) - indicated for high-risk characteristics:
    • NVD (neovascularization of disc) >1/4-1/3 disc area
    • Any NVD with preretinal or vitreous hemorrhage
    • NVE >1/2 disc area with hemorrhage
    • Any neovascularization of iris (NVI) or angle (NVA)
  2. Anti-VEGF therapy - alternative to PRP; preferred if DME coexists or vitreous hemorrhage limits the view to the peripheral retina. Note: patients lost to follow-up on anti-VEGF alone have worse outcomes than those receiving PRP.
  • The Wills Eye Manual, pp. 813-814

Differential Diagnosis

  • Central/Branch Retinal Vein Occlusion (CRVO/BRVO) - typically unilateral, sudden onset; hemorrhages follow venous distribution
  • Hypertensive retinopathy - flame-shaped hemorrhages, microaneurysms rare, AV nicking
  • Ocular Ischemic Syndrome (OIS) - hemorrhages in midperiphery, no exudates, usually painful
  • Radiation retinopathy - develops years after radiation; microaneurysms rare
  • Sickle cell retinopathy - peripheral "sea fan" neovascularization

Recent Evidence

A 2025 meta-analysis (PMID 39128789) comparing anti-VEGF vs. panretinal photocoagulation (PRP) for PDR found anti-VEGF injections to be an effective alternative to PRP laser therapy. AI-based screening tools are also rapidly advancing as a systematic approach to earlier DR detection (PMID 38885761).
Key takeaway: Diabetic retinopathy is preventable and treatable. Regular screening, tight glycemic and blood pressure control, and timely use of anti-VEGF therapy or laser treatment are the cornerstones of management.
This is a shared conversation. Sign in to Orris to start your own chat.